podofilox
Trade name: condylox
Approved
Dec 13, 1990
Podofilox ((abbreviated as PPT), otherwise known as podofilox) is an antimitotic drug which can be chemically synthesized or purified from the plant families Coniferae and Berberidaceae (e.g. species of Juniperus and Podophyllum). Podofilox 0.5% solution is indicated for the topical treatment of external genital warts (Condyloma acuminatum). This product is not indicated in the treatment of perianal or mucous membrane warts. Treatment of genital warts with podofilox results in necrosis of visible wart tissue. The exact mechanism of action is unknown, but is believed to exert its antimitotic effect by binding to tubulin, at a site close to but not identical to the binding site of colchicine; it is thought that this antimitotic effect causes necrosis of wart tissue, the observed clinical effect. In addition, podofilox is known to interfere with nucleoside transport, which may also contribute to its action. Adverse effects reported in less than 5% of the patients included pain with intercourse, insomnia, tingling, bleeding, tenderness, chafing, malodor, dizziness, scarring, vesicle formation, crusting edema, dryness/peeling, foreskin irretraction, hematuria, vomiting and ulceration. — NCATS
Clinical trial activity
1 trials · 2 clinical orgs · 6 marketing orgs
Earliest trial started Apr 20, 2018 (NCT03532776)
Timeline
1990s
2000s
- Jan 29, 2002
Paddock Laboratories — Marketing Organization
- Jan 29, 2002
Padagis Us — Marketing Organization
2010s
- Jul 21, 2010
Bausch & Lomb — Marketing Organization
- Jan 1, 2018
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Unspecified targetOTHER
Unknown
Microtubule inhibitor, but this is likely not the mode of action against HPV
Approval history
- approvedPriority reviewDec 13, 1990
Chemistry & pharmacology
SMILES
COC1=CC(=CC(OC)=C1OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@@H](O)C4=CC5=C(OCO5)C=C24- Mol. weight
- 414.4053 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Topical
- Availability
- Prescription Only
Oral
No
Parenteral
No
Topical
Yes
Sources
- WikipediaPodophyllotoxin ↗
- NCATSL36H50F353 ↗
- ChEMBLCHEMBL61 ↗
Also known as
- 9-hydroxy-5-(3,4,5-trimethoxyphenyl)-5,8,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(5ah)-one
- 9-hydroxy-5-(3,4,5-trimethoxyphenyl)-5,8,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(5ah)-one
- condyline
- condyline
- condyline
- condylox
- condylox
- condylox
- podofilox
- podofilox
- podofilox
- podofilox
- podofilox
- podofilox
- podofilox
- podophyllinic acid lactone
- podophyllinic acid lactone
- podophyllotoxin
- podophyllotoxin
- podophyllotoxin
- podophyllotoxin
- podophyllotoxin
- podophyllotoxin
- podophyllotoxin
- (-)-podophyllotoxin
- (-)-podophyllotoxin
- podophyllotoxin 7
- podophyllotoxin 7
- podophyllum
- podophyllum
- podophyllum
- ppt
- ppt
- warticon
- warticon
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03532776 | Phase 3 | Apr 20, 2018 | bioRASI, LLC, Hyloris Developments SA |
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| bioRASI, LLC | For profit | 1 | 1 | 1 | 2018 |
| Hyloris Developments SA | For profit | 1 | 0 | 1 | 2018 |
Marketing (9)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Allergan | For profit | MKTG | Dec 13, 1990 |
| Allergan | For profit | NDA2 | Dec 13, 1990 |
| Allergan | For profit | NDA | Dec 13, 1990 |
| Bausch & Lomb | For profit | MKTG | Jul 21, 2010 |
| Padagis Us | For profit | MKTG | Jan 29, 2002 |
| Paddock Laboratories | For profit | MKTG | Jan 29, 2002 |
| SmithKline Beecham | For profit | NDA2 | Mar 13, 1997 |
| Teva | For profit | MKTG | Dec 13, 1990 |
| Teva | For profit | NDA2 | Dec 13, 1990 |